The myth of the biotech revolution

被引:121
|
作者
Nightingale, P [1 ]
Martin, P
机构
[1] Univ Sussex, Freeman Ctr, Sci Policy Res Unit, Brighton BN1, E Sussex, England
[2] Inst Studies Biorisks & Soc, IGBIS, Nottingham NG7 2RD, England
基金
英国经济与社会研究理事会;
关键词
D O I
10.1016/j.tibtech.2004.09.010
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The existence of a medicinal 'biotech revolution' has been widely accepted and promoted by academics, consultants, industry and government. This has generated expectations about significant improvements in the drug discovery process, healthcare and economic development that influence a considerable amount of policy-making. Here we present empirical evidence, from a variety of indicators, that shows that a range of outputs have failed to keep pace with increased research and development spending. Rather than producing revolutionary changes, medicinal biotechnology is following a well-established pattern of slow and incremental technology diffusion. Consequently, many expectations are wildly optimistic and over-estimate the speed and extent of the impact of biotechnology, suggesting that the assumptions underpinning much contemporary policymaking need to be rethought.
引用
收藏
页码:564 / 569
页数:6
相关论文
共 50 条